CDR-Life

Executive Summary

CDR-Life is a Swiss biotechnology company pioneering the development of next-generation T cell engagers (TCEs) through its proprietary M-gager® platform. Founded in 2017 and headquartered in Zurich, the company focuses on creating highly selective immunotherapies for cancer and autoimmune diseases. The M-gager platform enables targeting of both conventional tumor antigens and previously undruggable intracellular targets, offering a potential breakthrough in treating solid tumors and autoimmune conditions. CDR-Life's approach leverages the power of the immune system while minimizing off-target effects, aiming to improve efficacy and safety profiles compared to traditional TCEs. The company is currently in Phase 2 clinical development, with its lead program targeting a validated yet difficult-to-treat antigen in solid tumors. Additionally, CDR-Life is exploring applications in autoimmune indications, expanding the therapeutic potential of its platform. With a strong intellectual property portfolio and a focus on innovation, CDR-Life represents a promising player in the immuno-oncology and autoimmune space.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 interim efficacy and safety data readout for lead TCE program in solid tumors60% success
• Q2 2026Initiation of Phase 2 clinical trial for autoimmune indication using M-gager platform80% success
• TBDPotential partnership or licensing deal for M-gager platform or lead asset30% success